|
Gilead’s PAH Candidate Scrapped After Missing Primary Endpoint in Study
Gilead Sciences’ pulmonary arterial hypertension (PAH) drug cicletanine did not meet its primary endpoint in a Phase II trial, leading Gilead to terminate the study and drop plans to further develop the drug for PAH.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives